| 黄丽,罗圣平,罗晓波,等.某医院2型糖尿病住院患者调脂药物应用情况分析[J].安徽医药,2016,20(12):2356-2359. |
| 某医院2型糖尿病住院患者调脂药物应用情况分析 |
| Application of lipid-regulating drugs among type 2 diabetes mellitus in one hospital |
| 投稿时间：2016-07-15 |
| DOI： |
| 中文关键词: 2型糖尿病 调脂药物 应用情况 心血管事件 |
| 英文关键词: Type 2 diabetes mellitus Lipid-regulating drug Application Cardiovascular events |
| 基金项目: |
|
| 摘要点击次数: 4706 |
| 全文下载次数: 7 |
| 中文摘要: |
| 目的 了解某医院2型糖尿病(T2DM)患者调脂药物应用情况,促进糖尿病调脂药物的合理应用。方法 选择资料完整的T2DM患者1 148例进行分析,评估患者心血管事件的风险因素,统计患者调脂药物使用情况,评估血脂控制达标情况。结果 1 148例T2DM患者中极高风险患者884例,较高风险患者256例,低风险患者8例。有990例(86.2%)使用了调脂药物。单用他汀类治疗950例(755例阿托伐他汀20 mg qn,194例瑞舒伐他汀钙10 mg qn,1例普伐他汀10 mg qn),单用贝特类治疗24例(均为非诺贝特200 mg qd),联合用药16例(14例联用非诺贝特200 mg qd+阿托伐他汀20 mg qd,2例联用吉非罗齐300 mg bid+阿托伐他汀20 mg qd)。血脂异常控制达标者367例,达标率为32.0%。结论 该院T2DM调脂药物使用率低,血脂控制达标率低,调脂药物的选择以他汀类为主,但未根据患者具体情况确定个体化的他汀类药物用药剂量。临床医生需提高T2DM患者心血管风险意识管理,遵循指南个体化给予调脂药物治疗。 |
| 英文摘要: |
| Objective To investigate the application of lipid-regulating drugs among type 2 diabetes mellitus (T2DM) hospitalized.Methods Data of 1 148 T2DM subjects were collected and analyzed.Risk factors of cardiovascular events for patients were evaluated,the use of lipid-regulating drugs was analyzed and the standard rate of lipid control was calculated.Results Among the 1148 T2DM cases 884 patients had very high risk,256 patients had high risk and 8 patients had low risk.Totally 990 patients(86.2%)took lipid-regulating drugs,among whom 950 patients took statins (755 atorvastatin 20 mg qn,194 rosuvastatin 10mg qn,1 pravastatin 10 mg qn) ,24 patients took clofibrates (fenofibrate 200 mg qd),16 patients took combined medication (14 fenofibrate 200 mg qd+atorvastatin 20 mg qd,2 gemfibrozil 300 mg bid+atorvastatin 20 mg qd).There were 367 patients whose lipid was controlled up to the standard,the standard rate of lipid control being 32.0%.Conclusions The usage rate of lipid-regulating drugs of type 2 diabetes mellitus is low,and the standard rate of lipid control is low.Statins are used on most occasions,but the dosage of administration is not individualized.Doctors should have more awareness of the risk management of CVD of the type 2 diabetes mellitus.The use of lipid-regulating drugs should be individualized as guidelines. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
